In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

被引：158

作者：

Arikan, S ^{[1
]}

Lozano-Chiu, M ^{[1
]}

Paetznick, V ^{[1
]}

Rex, JH ^{[1
]}

机构：

[1] Univ Texas, Sch Med, Ctr Study Emerging & Reemerging Pathogens, Deot Internal Med,Div Infect Dis, Houston, TX 77030 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 01期

关键词：

D O I：

10.1128/AAC.45.1.327-330.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

We investigated the relevance of prominent reduction in turbidity macroscopically (MIC) and formation of aberrant hyphal tips microscopically (minimum effective concentration; MEC) in measuring the in vitro activity of caspofungin against Aspergillus and Fusarium. Caspofungin generated low MICs and MECs against Aspergillus, but not for Fusarium. While MICs increased inconsistently when the incubation time was prolonged, MEC appeared as a stable and potentially relevant endpoint in testing in vitro caspofungin activity.

引用

页码：327 / 330

页数：4

共 26 条

[1] Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
Abruzzo, GK
Flattery, AM
Gill, CJ
Kong, L
Smith, JG
Pikounis, VB
Balkovec, JM
Bouffard, AF
Dropinski, JF
Rosen, H
Kropp, H
Bartizal, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2333 - 2338
[2] EVALUATION OF WATER-SOLUBLE PNEUMOCANDIN ANALOGS L-733560, L-705589, AND L-731373 WITH MOUSE MODELS OF DISSEMINATED ASPERGILLOSIS, CANDIDIASIS, AND CRYPTOCOCCOSIS
ABRUZZO, GK
FLATTERY, AM
GILL, CJ
KONG, L
SMITH, JG
KRUPA, D
PIKOUNIS, VB
KROPP, H
BARTIZAL, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) : 1077 - 1081
[3] Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species
Arikan, S
Lozano-Chiu, M
Paetznick, V
Nangia, S
Rex, JH
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (12) : 3946 - 3951
[4] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K
Gill, CJ
Abruzzo, GK
Flattery, AM
Kong, L
Scott, PM
Smith, JG
Leighton, CE
Bouffard, A
Dropinski, JF
Balkovec, J
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) : 2326 - 2332
[5] In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
DelPoeta, M
Schell, WA
Perfect, JR
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) : 1835 - 1836
[6] Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
Denning, DW
Radford, SA
Oakley, KL
Hall, L
Johnson, EM
Warnock, DW
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) : 401 - 414
[7] Echinocandins and pneumocandins - a new antifungal class with a novel mode of action
Denning, DW
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) : 611 - 614
[8] In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
Ernst, EJ
Klepser, ME
Ernst, ME
Messer, SA
Pfaller, MA
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 33 (02) : 75 - 80
[9] Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.
Ernst, ME
Klepser, ME
Wolfe, EJ
Pfaller, MA
[J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1996, 26 (3-4) : 125 - 131
[10] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
Espinel-Ingroff, A
[J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) : 2950 - 2956

← 1 2 3 →